A Medical Device Daily

Osteotech (Eatontown, New Jersey), a developer of biologic solutions for regenerative healing, reported that its Plexur Technology will be used in a craniofacial reconstruction program led by Jeffrey Hollinger, PhD, of Carnegie Mellon University (Pittsburgh).

This program, which was prepared under the auspices of the New Jersey Center for Biomaterials (Piscataway, New Jersey) and Joachim Kohn, PhD, of Rutgers University (also Piscataway), is part of a multi-institutional effort funded by a $42.5 million grant from the Armed Forces Institute of Regenerative Medicine (AFIRM).

The reconstruction program looks to create a new Plexur Biocomposite made of allograft bone fibers or particles and utilizes novel biodegradable polyurethane to facilitate healing and improve outcomes.

Osteotech previously obtained a license from Carnegie Mellon for the biodegradable polyurethane that is to be used in this program. The collaborative research efforts are directed in part, towards developing a biocomposite that has unique characteristics, including high compressive, torsional or bending strength.

Osteotech has the rights to any product developed within its current Plexur intellectual property estate and a non-exclusive right to any technology improvements.

The PlexurTechnology uses bone tissue for procedure-specific surgical applications in combination with a wide variety of polymers.